1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Wang, G. Treleaven, W.D. Cushley, R.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking NE Biochim.Biophys.Acta BBACAQ 0113 0006-3002 1301 174 184 10.1016/0005-2760(96)00037-9 8664326 Conformation of human serum apolipoprotein A-I(166-185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR and CD. Evidence for specific peptide-SDS interactions. 1996 10.2210/pdb1odq/pdb pdb_00001odq 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2336.605 APOA-I PEPTIDE RESIDUES 166 - 185 1 man polymer APOA-I (166 - 185), APOLIPOPROTEIN A-I (166 - 185) no no YSDELRQRLAARLEALKENG YSDELRQRLAARLEALKENG A polypeptide(L) n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens database_2 pdbx_database_status pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations Other 1 0 1996-06-10 1 1 2008-03-24 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site _pdbx_nmr_software.name Y BNL 1996-03-02 REL REL MOST CLOSELY RESEMBLING THE AVERAGE STRUCTURE OF OF A CALCULATED SET OF 20 CONFORMERS 20 5 3.7 310 K HAVEL refinement DGII BIOSYM TECHNOLOGIES, INC. refinement Discover TYR 1 n 1 TYR 1 A SER 2 n 2 SER 2 A ASP 3 n 3 ASP 3 A GLU 4 n 4 GLU 4 A LEU 5 n 5 LEU 5 A ARG 6 n 6 ARG 6 A GLN 7 n 7 GLN 7 A ARG 8 n 8 ARG 8 A LEU 9 n 9 LEU 9 A ALA 10 n 10 ALA 10 A ALA 11 n 11 ALA 11 A ARG 12 n 12 ARG 12 A LEU 13 n 13 LEU 13 A GLU 14 n 14 GLU 14 A ALA 15 n 15 ALA 15 A LEU 16 n 16 LEU 16 A LYS 17 n 17 LYS 17 A GLU 18 n 18 GLU 18 A ASN 19 n 19 ASN 19 A GLY 20 n 20 GLY 20 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 -5.49 0.90 118.30 112.81 A A A CB CG OD2 ASP ASP ASP 3 3 3 N 1 4.04 0.50 120.30 124.34 A A A NE CZ NH1 ARG ARG ARG 6 6 6 N 1 4.07 0.50 120.30 124.37 A A A NE CZ NH1 ARG ARG ARG 8 8 8 N 1 4.03 0.50 120.30 124.33 A A A NE CZ NH1 ARG ARG ARG 12 12 12 N 2 -5.49 0.90 118.30 112.81 A A A CB CG OD2 ASP ASP ASP 3 3 3 N 2 4.05 0.50 120.30 124.35 A A A NE CZ NH1 ARG ARG ARG 6 6 6 N 2 4.05 0.50 120.30 124.35 A A A NE CZ NH1 ARG ARG ARG 8 8 8 N 2 4.15 0.50 120.30 124.45 A A A NE CZ NH1 ARG ARG ARG 12 12 12 N 3 -5.49 0.90 118.30 112.81 A A A CB CG OD1 ASP ASP ASP 3 3 3 N 3 4.05 0.50 120.30 124.35 A A A NE CZ NH1 ARG ARG ARG 6 6 6 N 3 4.08 0.50 120.30 124.38 A A A NE CZ NH1 ARG ARG ARG 8 8 8 N 3 4.05 0.50 120.30 124.35 A A A NE CZ NH1 ARG ARG ARG 12 12 12 N 4 -5.51 0.90 118.30 112.79 A A A CB CG OD2 ASP ASP ASP 3 3 3 N 4 4.02 0.50 120.30 124.32 A A A NE CZ NH1 ARG ARG ARG 6 6 6 N 4 4.07 0.50 120.30 124.37 A A A NE CZ NH1 ARG ARG ARG 8 8 8 N 4 4.06 0.50 120.30 124.36 A A A NE CZ NH1 ARG ARG ARG 12 12 12 N 5 -5.50 0.90 118.30 112.80 A A A CB CG OD2 ASP ASP ASP 3 3 3 N 5 4.08 0.50 120.30 124.38 A A A NE CZ NH1 ARG ARG ARG 6 6 6 N 5 4.01 0.50 120.30 124.31 A A A NE CZ NH1 ARG ARG ARG 8 8 8 N 5 4.00 0.50 120.30 124.30 A A A NE CZ NH1 ARG ARG ARG 12 12 12 N 1 A A CD OE2 GLU GLU 4 4 0.110 0.011 1.252 1.362 N 1 A A CD OE2 GLU GLU 14 14 0.110 0.011 1.252 1.362 N 1 A A CD OE2 GLU GLU 18 18 0.110 0.011 1.252 1.362 N 2 A A CD OE2 GLU GLU 4 4 0.109 0.011 1.252 1.361 N 2 A A CD OE2 GLU GLU 14 14 0.110 0.011 1.252 1.362 N 2 A A CD OE2 GLU GLU 18 18 0.111 0.011 1.252 1.363 N 3 A A CD OE2 GLU GLU 4 4 0.110 0.011 1.252 1.362 N 3 A A CD OE2 GLU GLU 14 14 0.110 0.011 1.252 1.362 N 3 A A CD OE2 GLU GLU 18 18 0.109 0.011 1.252 1.361 N 4 A A CD OE2 GLU GLU 4 4 0.110 0.011 1.252 1.362 N 4 A A CD OE2 GLU GLU 14 14 0.109 0.011 1.252 1.361 N 4 A A CD OE2 GLU GLU 18 18 0.110 0.011 1.252 1.362 N 5 A A CD OE2 GLU GLU 4 4 0.110 0.011 1.252 1.362 N 5 A A CD OE2 GLU GLU 14 14 0.110 0.011 1.252 1.362 N 5 A A CD OE2 GLU GLU 18 18 0.110 0.011 1.252 1.362 N 1 A ASP 3 -96.28 39.65 2 A ASP 3 -95.36 38.83 3 A ASP 3 -97.15 36.00 4 A ASP 3 -98.65 39.87 PEPTIDE OF HUMAN APOA-I RESIDUES 166-185. NMR, 5 STRUCTURES AT PH 3.7, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:40 1 Y N A LEU 5 A LEU 5 HELX_P A GLU 18 A GLU 18 1 1 14 LIPID TRANSPORT APOLIPOPROTEIN A-I, COFACTOR FOR LCAT ACTIVATION, LIPID TRANSPORT APOA1_HUMAN UNP 1 1 P02647 MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTST FSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHE LQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQ GLLPVLESFKVSFLSALEEYTKKLNTQ 190 209 1ODQ 1 20 P02647 A 1 1 20 1 P 1